Scientific Highlights

Christoph Umbricht won the August-Abegg-Fonds Prize for the best oral presentation at the Doktorandentag autumn session 2018

The Doktorandentag gives second- or third-year PhD students of the Institute of Pharmaceutical Sciences or associated institutions the opportunity to present their research projects. Mr. Umbricht presented his work entitled "Preclinical development of novel PSMA-targeting radioligands - modulation of albumin-binding properties to improve prostate cancer therapy".


Araris Biotech has been ranked TOP 5 in the business plan competition of venture

Araris Biotech which is currently in foundation from the Center for Radiopharmaceutical Sciences (CRS, Prof. Roger Schibli) of BIO at PSI, has been ranked TOP 5 in the business plan competition of venture. The spin-off will be focused on the development of antibody-drug conjugates (ADCs) having a well-defined and optimal antibody-to-drug ratio. The technology will be used to establish a drug development platform for targeted therapies and diagnostic applications.
More Information
Video presentation of Araris Biotech


Christoph Umbricht has been awarded for the best oral presentation at the 7th Cancer Biology PhD Student Retreat which took place in Ascona from March 26 to March 28, 2018.

The award has been attributed for an excellent oral presentation entitled "Albumin-binding PSMA radioligands – optimization of the tissue distribution profile".



Petersen Investigator award in 2018 goes to the Center for Radiopharmaceutical Sciences at PSI

The Neuroendocrine Tumor Research Foundation (NETRF) is committed to funding the most promising research in order to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers. In January 2018 the Board of Directors has awarded a Petersen Investigator award to Professor Roger Schibli and his team for the research proposal entitled, “Simultaneous Auger-Electron and β--Particle Therapy of Metastasized NET Using 161Tb-DOTATOC”. The proposal emphasizes the multidisciplinary talents of the Center of Radiopharmaceutical Sciences, from radionuclide development (Dr. Nick van der Meulen) via preclinical research (PD Dr. Cristina Müller) to Good Manufacturing Practice (Susanne Geistlich). The final goal of this research project is to make 161Tb-DOTATOC available for clinical application.
More Information



Simon Käppeli won the Anton-Lehmann-Fonds Prize for the best oral presentation at the Doktorandentag spring session 2018

The Doktorandentag gives second- or third-year PhD students of the Institute of Pharmaceutical Sciences or associated institutions the opportunity to present their research projects. Mr. Käppeli presented his work entitled "Targeting the GLP-1 receptor on pancreatic beta-cells: signaling and radiopharmaceutical application".


Congratulations to Dr. Philipp Spycher, finalist for the Swiss Technology Award 2017 (Category «Inventors»)!

More Information
Presentation of the projects in the category "Inventors"


Congratulations to Dr. Cristina Müller, winner of the Ruzicka Prize 2014!

More Information



Mit Vitamin gegen Krebs

Forschung mit radioaktiv markierten Folsäure-Verbindungen
Täglich nehmen wir mit unserer Nahrung Folsäure auf. Dieses Vitamin ist wichtig für die Zellteilung und somit für das Wachstum. Doch in Zukunft könnte dem Vitamin noch eine weitere Rolle zukommen. Denn am PSI werden Therapien gegen Krebs entwickelt, die Folsäure nutzen.
Weitere Information


BetaCure

The Center Radiopharmaceuticals Sciences is a member of the FP7 consortium “BetaCure”, a collaboration between 17 research institutions and companies throughout whole Europe. The aim of the project “Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology” is to develop new treatment modalities for rare beta-cell derived hyperinsulinemic diseases like Nesidioblastosis or Insulinoma. Nesidioblastosis is a hyperplasia of the beta-cells which lead to a hyperproduction of insulin in newborns. Insulinomas are tumors derived from beta-cells. These diseases are potential life threatening because of its hypoglycemic pattern and have only limited therapeutic modalities. The consortium is clinical oriented with a strong part of preclinical research and has a close collaboration with patient organizations related to these diseases. The project started on 1st of April 2014.


Development of radiolabeled antibodies for clinical diagnosis of invasive Aspergillosis by PET imaging

The Center for Radiopharmaceutical Sciences is a research partner in the project entitled “New Molecular-Functional Imaging Technologies and Therapeutic Strategies for Theranostic of Invasive Aspergillosis” (MATHIAS) funded by the European Union in the 7th Framework Programme. The main goal of this collaborative project is the development of radiolabeled antibodies for clinical diagnosis of invasive Aspergillosis by PET imaging. The preclinical evaluation of different antibody fragments for imaging and radioimmunotherapy are additional goals of MATHIAS. The project started on 1st October 2013 and the duration of the project is five years.
More Information


Awards

Cancer Network Zurich-Cancer Biology Ph.D. Program Travel Grant:
The Cancer Biology Ph.D. Program awarded a travel grant to NASTASSJA TERRANEO to visit the 25th Annual Meeting of AGRR 2017 in Munich.

SIMON KÄPPELI also received a travel grant in 2017 to work with Professor Martin Gotthardt at the Radboud University Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, Netherlands on a BetaCure project


%FIDEFINED%
  • Foto_Top_5_Philipp.jpg:
    Foto Top 5 Philipp.jpg